Literature DB >> 9069613

Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients.

M Maltoni1, L Fabbri, O Nanni, E Scarpi, L Pezzi, E Flamini, A Riccobon, S Derni, G Pallotti, D Amadori.   

Abstract

Cancer anorexia-cachexia syndrome (CACS), which is characterized by progressive weight loss (WL) and anorexia (A), is present in 50% of advanced cancer patients and in 80% of terminally ill cancer patients. One of the most controversial aspects of CACS is its oetiopathogenesis; experimental studies have identified certain cytokines [Tumour necrosis factor alpha (TNF-alpha), interleukin 1 (IL-1), interleukin 6 (IL-6), and gamma interferon (gamma-IFN)] as possible co-factors in the onset of the syndrome. The aim of our study was to investigate the correlation between serum levels of circulating cytokines and severity of CACS. The following series of parameters was identified in 61 patients with advanced and terminal cancer: stage of disease; Karnofsky performance status (KPS) and clinical symptoms; biohumoral, anthropometric and immunological situation; level of circulating cytokines. All these parameters were evaluated for a possible link with WL/A. Our data do not show any significant correlation between circulating cytokines and WL/A. A direct correlation was identified between WL/A and nausea (P = 0.03 and P < 0.001, respectively) whereas inverse correlations were observed for both factors as regards arm circumference (P < 0.001 for both), wrist circumference (P < 0.001 for both), KPS (P < 0.001 and P = 0.003, respectively) and creatinine (P = 0.005 and P = 0.03, respectively). Other biochemical factors, such as haemoglobin, haematocrit, glycaemia, prealbumin, sodium and chlorine were also correlated with at least one of two clinical parameters in question. Unexpected results were seen in the increases in CD20 and CD4 and in the CD4/CD8 ratio. Serum levels of these cytokines do not, therefore, appear to be critical in the onset of CACS. On the contrary, our findings confirmed the clinico-laboratory picture that is characteristic of CACS. If we consider the possibility that CACS is provoked by an aspecific response of the host's defence mechanisms against prolonged neoplastic attack, the increase in CD4 (helper lymphocytes) could be linked to the persistent response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9069613     DOI: 10.1007/bf01262570

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  27 in total

Review 1.  Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity.

Authors:  K Bendtzen
Journal:  Immunol Lett       Date:  1988-11       Impact factor: 3.685

2.  Therapeutic and toxic activity of tumor necrosis factor is synergistic with gamma interferon.

Authors:  J E Talmadge; O Bowersox; H Tribble; M Shepard; D Liggitt
Journal:  Pathol Immunopathol Res       Date:  1989

3.  Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia.

Authors:  M Mori; K Yamaguchi; K Abe
Journal:  Biochem Biophys Res Commun       Date:  1989-05-15       Impact factor: 3.575

4.  Lipolytic factors associated with murine and human cancer cachexia.

Authors:  S A Beck; H D Mulligan; M J Tisdale
Journal:  J Natl Cancer Inst       Date:  1990-12-19       Impact factor: 13.506

5.  Serum tumor necrosis factor does not correlate with changes in muscle volume in children with malignancies.

Authors:  M A Siimes; A M Teppo; E K Koskelo; U M Saarinen
Journal:  Pediatr Hematol Oncol       Date:  1991 Jan-Mar       Impact factor: 1.969

6.  Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients.

Authors:  A Waage; T Espevik; J Lamvik
Journal:  Scand J Immunol       Date:  1986-12       Impact factor: 3.487

7.  Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models.

Authors:  B A Sherry; J Gelin; Y Fong; M Marano; H Wei; A Cerami; S F Lowry; K G Lundholm; L L Moldawer
Journal:  FASEB J       Date:  1989-06       Impact factor: 5.191

8.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention.

Authors:  L D Butler; N K Layman; R L Cain; P E Riedl; K M Mohler; J L Bobbitt; R Belagajie; J Sharp; A M Bendele
Journal:  Clin Immunol Immunopathol       Date:  1989-12

10.  Raised serum levels of tumour necrosis factor in parasitic infections.

Authors:  P Scuderi; K E Sterling; K S Lam; P R Finley; K J Ryan; C G Ray; E Petersen; D J Slymen; S E Salmon
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

View more
  24 in total

Review 1.  [Pathophysiology of catabolism in undernurished elderly patients].

Authors:  D Baez-Franceschi; J E Morley
Journal:  Z Gerontol Geriatr       Date:  1999-07       Impact factor: 1.281

Review 2.  Anorexia in cancer: role of feeding-regulatory peptides.

Authors:  Simona Perboni; Akio Inui
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 3.  Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Authors:  Manuela Schmidinger; Romano Danesi
Journal:  Oncologist       Date:  2017-11-16

4.  Mechanisms of Cachexia in Chronic Disease States.

Authors:  Tadashi Yoshida; Patrice Delafontaine
Journal:  Am J Med Sci       Date:  2015-10       Impact factor: 2.378

Review 5.  Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.

Authors:  Erin E Talbert; Denis C Guttridge
Journal:  Semin Cell Dev Biol       Date:  2015-09-16       Impact factor: 7.727

6.  Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial.

Authors:  Aminah Jatoi; James Egner; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; Shaker R Dakhil; James A Mailliard; George G Klee; James E Krook
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

7.  [Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].

Authors:  V Lieb; M Rink; D Sikic; B Keck
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

Review 8.  Cancer cachexia.

Authors:  Michael J Tisdale
Journal:  Langenbecks Arch Surg       Date:  2004-05-28       Impact factor: 3.445

Review 9.  The role of inflammatory pathways in cancer-associated cachexia and radiation resistance.

Authors:  Aaron Laine; Puneeth Iyengar; Tej K Pandita
Journal:  Mol Cancer Res       Date:  2013-06-20       Impact factor: 5.852

Review 10.  The role of triglyceride lipases in cancer associated cachexia.

Authors:  Suman K Das; Gerald Hoefler
Journal:  Trends Mol Med       Date:  2013-03-14       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.